TG Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Net Income	41.2	12.67	-198.34	-348.1	-279.38	-172.87	Upgrade
Depreciation & Amortization	0.17	0.21	0.3	0.28	0.16	0.1	Upgrade
Share-Based Compensation	40.45	37.93	19.19	61.27	80.29	11.34	Upgrade
Other Operating Activities	-61.54	-82.23	2.68	-9.09	-15.57	28.63	Upgrade
Operating Cash Flow	20.28	-31.41	-176.17	-295.63	-214.51	-132.81	Upgrade
Capital Expenditures	0	0	-0.01	-0.4	-0.36	-0.13	Upgrade
Change in Investments	-53.74	-50.65	-20	0.07	-24.15	-0.59	Upgrade
Investing Cash Flow	-53.74	-50.65	-20.01	-0.33	-24.51	-0.72	Upgrade
Share Issuance / Repurchase	47.48	47.83	0.58	2.44	679.83	175.02	Upgrade
Debt Issued / Paid	0	25	-0.98	40	0	29.99	Upgrade
Other Financing Activities	-	-0.13	-	-1.02	-	-0.8	Upgrade
Financing Cash Flow	47.48	72.71	-0.39	41.42	679.83	204.21	Upgrade
Net Cash Flow	14.02	-9.36	-196.57	-254.55	440.81	70.69	Upgrade
Free Cash Flow	20.28	-31.41	-176.18	-296.04	-214.86	-132.94	Upgrade
Free Cash Flow Margin	7.01%	-13.44%	-6326.18%	-4425.70%	-141357.89%	-87458.55%	Upgrade
Free Cash Flow Per Share	0.14	-0.22	-1.30	-2.24	-1.86	-1.50	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).